But PFS data are lacking, and there are questions about first and second-line plans.

Three private biotechs enter clinical trials, one targeting KRAS.

Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.

Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.

$650m buys the group rights to RemeGen’s RC148.

After Aktis's $318m flotation Eikon is a bigger proposition.

Readout of the Pivot-006 trial is brought forward by nearly a year.

Prexasertib data worsen again, and biomarkers are up in the air.